Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Research Design | 2 | 2019 | 729 | 0.920 |
Why?
|
| Bayes Theorem | 3 | 2019 | 307 | 0.870 |
Why?
|
| Endpoint Determination | 1 | 2019 | 82 | 0.650 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 317 | 0.620 |
Why?
|
| Serum Albumin, Human | 1 | 2017 | 10 | 0.610 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 61 | 0.580 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.510 |
Why?
|
| Computer Simulation | 1 | 2019 | 706 | 0.510 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.490 |
Why?
|
| Liver Failure, Acute | 3 | 2021 | 49 | 0.470 |
Why?
|
| Stroke Rehabilitation | 3 | 2022 | 335 | 0.420 |
Why?
|
| Phenytoin | 2 | 2020 | 27 | 0.360 |
Why?
|
| Valproic Acid | 2 | 2020 | 93 | 0.340 |
Why?
|
| Status Epilepticus | 2 | 2020 | 74 | 0.330 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 131 | 0.320 |
Why?
|
| Anticonvulsants | 2 | 2020 | 223 | 0.310 |
Why?
|
| Sample Size | 1 | 2015 | 79 | 0.250 |
Why?
|
| Statistics as Topic | 1 | 2015 | 219 | 0.240 |
Why?
|
| Clinical Protocols | 1 | 2015 | 172 | 0.240 |
Why?
|
| Stroke | 3 | 2022 | 2162 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7028 | 0.210 |
Why?
|
| Recovery of Function | 3 | 2022 | 506 | 0.200 |
Why?
|
| Acetaminophen | 3 | 2021 | 111 | 0.200 |
Why?
|
| Walking | 1 | 2014 | 241 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 45 | 0.200 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 334 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 319 | 0.180 |
Why?
|
| Hepcidins | 1 | 2019 | 6 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 328 | 0.170 |
Why?
|
| Benchmarking | 1 | 2019 | 91 | 0.160 |
Why?
|
| Probability | 1 | 2019 | 244 | 0.160 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.160 |
Why?
|
| Exercise | 1 | 2014 | 658 | 0.160 |
Why?
|
| Evoked Potentials, Motor | 1 | 2018 | 63 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 9 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1745 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2018 | 190 | 0.150 |
Why?
|
| Ischemia | 1 | 2018 | 229 | 0.140 |
Why?
|
| Iron | 1 | 2019 | 197 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 295 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 167 | 0.140 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2018 | 111 | 0.140 |
Why?
|
| Motor Cortex | 1 | 2018 | 158 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2019 | 3703 | 0.130 |
Why?
|
| Humans | 13 | 2022 | 68549 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 1341 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2014 | 109 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 254 | 0.100 |
Why?
|
| Hand | 2 | 2022 | 90 | 0.100 |
Why?
|
| Algorithms | 1 | 2017 | 1195 | 0.100 |
Why?
|
| Upper Extremity | 2 | 2022 | 112 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2014 | 400 | 0.090 |
Why?
|
| Middle Aged | 7 | 2021 | 21119 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2020 | 1738 | 0.070 |
Why?
|
| Aged | 4 | 2021 | 14842 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 5710 | 0.060 |
Why?
|
| Adult | 5 | 2021 | 21379 | 0.060 |
Why?
|
| Male | 6 | 2021 | 37283 | 0.060 |
Why?
|
| Female | 6 | 2021 | 38021 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 8904 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2014 | 98 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2020 | 3187 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2014 | 183 | 0.050 |
Why?
|
| Thrombelastography | 1 | 2021 | 19 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 44 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 4843 | 0.040 |
Why?
|
| Hypotension | 1 | 2019 | 74 | 0.040 |
Why?
|
| Age Distribution | 1 | 2020 | 319 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2019 | 130 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 223 | 0.040 |
Why?
|
| Child | 2 | 2020 | 6401 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 929 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.040 |
Why?
|
| United States | 2 | 2019 | 7338 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 601 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1851 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 948 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1860 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 306 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3256 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 20880 | 0.010 |
Why?
|